

## Modeling the effects of tetanus vaccination on chronically infected HIV patients

L. E. Jones and A. S. Perelson  
Theoretical Biology and Biophysics Group  
Los Alamos National Laboratory  
Los Alamos, NM 87545

### Abstract

T-cell activation plays a critical role in the initiation and propagation of HIV-1 infection and yet transient activation of the immune system is a normal response to immunization. In this study we extend a simple model of HIV infection to include T cell activation by vaccination. We then show that the model can reproduce many but not all of the features of the post-tetanus immunization rise in viral load observed and reported on by Stanley et al., [ *N. Engl. J. Med.*, 334:1222–1230 (1996)]. Amplitudes and approximate timing of post-immunization maximum viremia were matched in nine of twelve cases; in patients with double peaks of nearly equal amplitude the later peaks were matched. Patients with single early peaks in their viremia were best fit with relatively high antigen clearance rate constants, while patients with early and late peaks in viremia of equal or nearly equal amplitude were best-fit with much lower clearance rates. The rate of clearance may depend on the level of pre-existing antibody, which in turn would be expected to depend on the time since the individual under study received a previous tetanus vaccination.

# 1 Introduction

T-cell activation plays a critical role in HIV infection and progression to AIDS [Fauci, 1993, Stanley et al., 1996, Wahl and Orenstein, 1997] In vitro studies have demonstrated the importance of cell activation in establishing productive HIV infection. Studies by Zack et al., [1990] and Bukrinsky et al., [1991] have shown that within resting cells reverse transcription may be incomplete and integration of proviral DNA may not occur, resulting in abortive infection. In contrast, activated peripheral blood mononuclear cells are readily infected in culture [Zack et al.,1990, Bukrinsky et al.,1991, Folks et al., 1986]. The course of HIV infection in vivo appears to be influenced by cell activation. High levels of activated peripheral T cells are a predictor of early progression to AIDS [Levacher et al., 1990, Giorgi and Detels, 1989], and chronic immune activation due to frequent and repeated parasitic infection has been suggested as the probable cause of the increased rate of HIV progression to AIDS and the greater susceptibility to infection observed in sub-Saharan Africa as compared to the developed countries [Medley et al., 1987, Bentwich et al., 1995, Weissman et al., 1996].

Transient activation of the immune system occurs during infections and is a normal response to immunization. Such activation can affect the course of HIV infection. Numerous studies have examined the consequences of vaccinating untreated HIV-infected individuals. Stanley et al. [1996] found that giving a booster dose of tetanus toxoid resulted in transient increases in plasma viremia in all 13 HIV-infected subjects studied. Staprans et al. [1995] found that influenza vaccination led to transient increases of plasma HIV-1 RNA, and that patients with higher CD4 T-cell counts had larger and more rapid increases in viral load. The large immunization-related increases in virus observed by Staprans et al. [1995] suggest that increased viral replication is not correlated only with antigen-specific T-cells, but that the activated influenza-specific cells must have recruited other non-specific T-cell populations, which then became targets for infection [Wahl and Orenstein, 1997].

Other studies using influenza vaccination and pneumococcal vaccine have confirmed that vaccination can trigger increases in plasma HIV RNA [O'Brien et al., 1995, Brichacek et al., 1996, Glesby et al., 1996, Rosok et al., 1996]. Thus a number of data sets are available that illustrate a relationship between immune system activation and changes in HIV viral load. This data presents an interesting challenge to current mathematical models of HIV infection [Perelson et al., 1996, 1997; Nowak and May, 2001]. In an early theoretical paper, McLean and Nowak [1992] examined the effects of infection with pathogens other than HIV as a cofactor in HIV progression. However, no quantitative data was available at the time for direct comparison of model and theory. Here we return to this issue and construct a simple model of HIV-infection and immune system activation via vaccination, and then compare the

model with data from the study of Stanley et al.[1996] in which 13 HIV seropositive, asymptomatic individuals were vaccinated with tetanus toxoid.

## 2 A simple vaccination model

To understand the effects of vaccination with a common recall antigen (tetanus toxoid) on chronically infected, untreated HIV patients whose viral loads have reached steady state, we modify what has become a standard HIV infection model [Perelson et al., 1996, 1997]. The model includes uninfected, infected and chronically infected T-cell populations, HIV and other antigens  $A$ . We assume that the vaccine-introduced antigens,  $A$ , activate CD4+ T-cells. For simplicity, the model ignores latently infected cells, which in untreated individuals are an extremely minor source of virus; Chun and Siliciano [1997] estimate that only 1 in  $10^5$  T cells are latently infected. We also do not separately consider vaccine-specific or HIV specific T-cell populations, since this leads to a model with more parameters than the data reported by Stanley et al., [1996] will support.

The model, like that of McLean and Nowak [1992], includes a vaccine antigen  $A$ , which we assume is eliminated from the body at a rate proportional to both the antigen concentration and the CD4+ T cell density. The rate of proportionality  $\gamma$  implicitly includes a factor that accounts for the fact that only a fraction of T cells are antigen specific and accounts for complexities of the antigen specific, helper cell dependent response that leads to antigen elimination.

Since individuals would be expected to vary with regard to the time of their last tetanus vaccination, we assume that levels of antibody and T memory cells specific for tetanus toxoid would also vary. In our model we avoid this level of detail, but simply assume that the antigen clearance rate and parameters that determine the rate of T cell activation vary for each patient.

The model we use is given by the following system of differential equations:

$$\begin{aligned}
 (1) \quad & \frac{dA}{dt} = -\gamma AT \\
 (2) \quad & \frac{dT}{dt} = \lambda + a\left(\frac{A}{A+K}\right)T - dT - kVT \\
 (3) \quad & \frac{dT^*}{dt} = (1-\alpha)kVT - \delta T^* \\
 (4) \quad & \frac{dC}{dt} = \alpha kVT - \mu C \\
 (5) \quad & \frac{dV}{dt} = N\delta T^* + N_c\mu C - cV
 \end{aligned}$$

where  $A$  is the vaccine antigen,  $T$  are uninfected CD4+ T cells,  $T^*$  are productively infected cells,  $C$  are chronically infected cells, and  $V$  represents HIV. Vaccine antigen

Table 1. Model Parameters

Parameter	Value	Reference
$\lambda$	$1 \times 10^4 ml^{-1} d^{-1}$	<i>Callaway and Perelson, 2001</i>
$d$	$0.01 d^{-1}$	<i>Mohri et al., 1998</i>
$\delta$	$0.7 d^{-1}$	<i>Perelson et al., 1996</i>
$\alpha$	0.195	<i>Callaway and Perelson, 2001</i>
$\mu$	$0.07 d^{-1}$	<i>Perelson et al., 1996</i>
$N_c$	$4.11 d^{-1}$	<i>Callaway and Perelson, 2001</i>
$c$	$13 d^{-1}$	<i>Mittler et al., 1999; Ferguson et al., 1999</i>

is cleared in a T cell-dependent manner with rate constant  $\gamma$ . Uninfected T cells,  $T$ , are produced at a rate  $\lambda$ , die at a rate  $d$ , and are infected by virus with rate constant  $\kappa$ . In the presence of antigen, we assume T cells are activated into proliferation at a maximum rate  $a$ , and that the proliferation rate depends on the antigen concentration with a half-saturation constant  $K$ .  $K$  is thus the antigen concentration that drives T cell proliferation to half its maximal value. Productively infected cells,  $T^*$ , are generated by infection of target T-cells  $T$  at a rate  $kVT$ , and die at rate  $\delta$ , as in the standard model [Perelson et al., 1996]. Chronically infected T-cells,  $C$ , are produced from healthy susceptible T-cells at a rate  $\alpha kVT$ , where  $\alpha < 1$ . Thus, the production of chronically infected cells occurs at a fraction of the rate of generating productively infected cells. Chronically infected cells die at a rate  $\mu$ , which we assume is less than  $\delta$ , so that chronically infected cells are longer-lived than productively infected cells. Free virus,  $V$ , is produced by productively infected cells at average rate  $N\delta$ , by chronically infected cells at rate  $N_c\mu$ , and is cleared at rate  $c$  per virion. The model parameters and their assumed values are given in Table 1.

Prior to vaccination, each patient was assumed to be in steady state with a known baseline T cell count  $\bar{T}$  and viral load  $\bar{V}$ . The steady state productively infected and chronically infected cell concentrations  $\bar{T}^*$  and  $\bar{C}$ , the infection rate constant  $k$  and burst size  $N$  may be calculated from the following steady state equations, derived by setting the left-hand sides of equations (2)-(5) to zero.

$$(6) \quad k = \frac{\lambda - d\bar{T}}{\bar{V}\bar{T}}$$

$$(7) \quad \bar{T}^* = \frac{1}{\delta}(1 - \alpha)(\lambda - d\bar{T})$$

$$(8) \quad \bar{C} = \frac{\alpha}{\mu}(\lambda - d\bar{T})$$

$$(9) \quad N = \frac{c\bar{V} - N_c\mu\bar{C}}{\delta\bar{T}^*}$$

Parameters other than  $k$  and  $N$  were set as shown in Table 1. Note that with these parameter choices, and the T cell and viral load levels in the patients studied by

Stanley et al., [1996] this model generally yields larger steady state levels of chronically infected cells than of productively infected cells (Table 2).

At time  $t = 0$ , we assume a dose of antigen  $A_0$  was given in a vaccine, which perturbed the steady state. We assume the same dose of vaccine was give to all individuals, and then measure the antigen concentration in each individual as a fraction of the immunizing dose. This is equivalent to setting  $A_0 = 1$ . We then numerically solved the system of differential equations given by (1) - (5), with the initial conditions  $A(0) = 1$ , and  $T$ ,  $T^*$ ,  $C$ , and  $V$  set to their steady state value. For each individual in the Stanley et al. [1996] study, the parameters  $K$ ,  $a$  and  $\gamma$  were allowed to vary so that the amplitude and timing of the response could be best matched to the observed post-vaccination viremia.

### 3 Data and sampling

Stanley *et al.*, (1995) studied 16 asymptomatic homosexual men seropositive for HIV-1. The subjects were given an 0.5 ml tetanus booster intramuscularly or mock immunized (three seropositive subjects and four seronegative controls). No information on prior vaccination history, i.e., date of last tetanus booster, or general quality of health was given. It was noted that one patient developed cavitary pneumonia about a month following vaccination.

The model was fit to the data on viral load changes after vaccination for each HIV-infected person studied by Stanley *et al.* (1996). Using nonlinear regression techniques, the best-fit set of parameters were determined for each patient (Table 3).

During the course of the original study, viral load measurements were taken on days 0 (baseline), 3, 7, 14, 21, 28 and 42 approximately. The data sampling was too sparse to determine the exact peak of viremia or the time the peak was attained. However, Stanley *et al.* (1996) report the apparent peak and the time it was measured. In addition, many patients had *two* post-immunization peaks in viremia. The greatest peak in viremia was the earlier of the two observed peaks in patients 3, 5, 10, and 13, and the second of two peaks in patients 1,4,7, and 11. Other patients had two peaks of nearly equal amplitude [patients 2, 8, 9].

Of the patients with double post-immunization peaks in viremia, patients 1, 7, 8, 9 and 11 had peaks at days 7 and 21 (Figure 1), though in some of these cases the earlier peaks can be classified as minor peaks or inflection points. Of those with single observed post-immunization peaks, patients 3, 5, 10 and 13 have primary peaks at day 7, and inflection points, shoulders, or minor peaks at day 28 (Figure 2).

Table 2. Baseline characteristics and post-immunization plasma viremia

Patient No.	T-cell count cells/mm <sup>3</sup>	Viremia,baseline copies/ml	Viremia,peak copies/ml	$V_f$	$\bar{T}^*$ cells/mm <sup>3</sup>	$\bar{C}$ cells/mm <sup>3</sup>
1.	362	147,000	437,000 (21/20)*	2.97	10.3	17.8
2.	271	3,850	10,500 (14,28/23)	2.73	8.4	20.3
3.	350	120,000	900,000 (7/9)	7.50	7.5	18.1
4.	389	100,000	700,000 (3,21/21)	7.00	7.0	17.0
5.	586	21,000	45,000 (3/20)	2.14	4.7	11.5
6.	336	215,000	725,000 (7/9)	3.37	7.6	18.5
7.	336	75,000	315,000 (7,21/18)	4.20	7.6	18.5
8.	361	87,500	241,000 (7,21/21)	2.75	7.3	17.8
9.	497	220,000	745,000 (7,21/21)	3.38	5.8	14.0
10.	615	10,500	375,000 (7/8)	35.7	10.8	26.1
11.	363	80,000	225,000 (7,21/19)	2.81	7.3	17.7
12.						
13.	8	1,550,000	4,970,000 (7/2)	3.21	11.4	27.6

\*First number(s) represent observed time(s) and second number is modeled time to peak viremia (days).

## 4 Results

The amplitude and the approximate timing of the post-immunization maximum viremia were matched in nine of twelve cases; in patients with double peaks of nearly equal amplitude (i.e., patients 8, 9), the later peaks were matched. The eleven patients modeled are summarized below and in Tables 2 and 3.

### 4.1 Early peaks in Viremia

Patients with relatively high baseline CD4 T-cell counts (patients 5, 9, 10), as well as those with high baseline viremia (patients 6, 9, 13) all had early peak viremia, at either 3 days (patient 5) or 7 days (patients 6, 9, 10, 13) post-immunization. This makes sense given the fact that high baseline T-cell counts yield a larger population of activated target cells post-immunization: a vigorous early response by the immune system ensures an early peak in viremia.

The “viremia factor”, or ratio of peak viremia to baseline viremia, given as  $V_f$  in Table 2, was generally rather low for most patients, ranging between 2 and 4 (mean = 2.92) for nine of twelve patients. Three remaining patients with unusually high “viremia factor” ratios, patients 3 ( $V_f = 7.5$ ), 4 ( $V_f = 7.0$ ) and 10 ( $V_f = 35.7$ ) also had early peaks, though in patient 4 this was a minor inflection followed by peak viremia at 21 days, whereas both patients 3 and 10 had single early peaks.

We were able to match well the amplitude and timing of peak viremia for patients 3, 6, and 10 (Figures 3, 4, and 5), all of whom had early peaks in viremia and were best-fit with relatively high antigen clearance rate constants,  $\gamma$ , in our simulations (Table 3).

Table 3. Best-fit parameter values for modeling post-immunization plasma viremia

Patient No.	$k$	$N$	$a$	$K$	$\gamma$
1.	$1.198933e^{-7}$	371	1.01	51.2	$7.0002e^{-8}$
2.	$6.987108e^{-6}$	8	2.08	<i>0.333</i>	$4.1562e^{-7}$
3.	$1.547619e^{-7}$	297	1.28	<i>2.43</i>	$1.7475e^{-6}$
4.	$1.570694e^{-7}$	263	2.50	39.5	$1.0840e^{-7}$
5.	$3.364213e^{-7}$	81	1.20	50.8	$8.5322e^{-7}$
6.	$9.191583e^{-8}$	523	2.49	<i>0.133</i>	$5.4999e^{-5}$
7.	$2.634920e^{-7}$	181	1.77	69.0	$1.0000e^{-7}$
8.	$2.022952e^{-7}$	220	1.69	83.3	$1.46793e^{-7}$
9.	$4.600329e^{-8}$	705	1.85	83.2	$1.17863e^{-7}$
10.	$6.29647e^{-7}$	43	5.00	<i>0.467</i>	$8.08425e^{-6}$
11.	$2.19353e^{-7}$	202	1.91	83.3	$1.4679e^{-7}$
12.					
13.	$8.000e^{-7}$	2522	0.956	$1.84e^{-8}$	$1.20708e^{-4}$

## 4.2 Double peaks in Viremia

Over half of the patients studied had multiple peaks in viremia, though often the first peak might be classified as ‘minor’. For patients with a minor early peak, usually at 7 days, followed by a maximum in viral load at 21 days, we were able to fit the amplitude and timing of the maximum peak. Patients 1, 4, 7, and 11 exemplify this behavior; results for patient 7 are shown in Figure 6. These patients were best-fit with  $\gamma$  values that were low relative to those given for patients with true early peaks in viremia (Table 3).

Some patients experienced early and late peaks in viremia of equal or nearly equal amplitude. Of the patients with double peaks in viremia, our model generally fit the later peaks at 21 days. These patients were assigned much lower clearance rates than were the patients who experienced single early peaks in viremia. However, in patients with double peaks (e.g., patients 8 and 9, Figures 7 and 8) fits to the earlier peaks, unobtainable with this model, might require higher values of  $\gamma$ .

## 4.3 T-cell - Antigen Interactions

The rate of antigen induced T-cell activation/proliferation is given in the model by  $a(\frac{A}{A+K})$  [equations 2 and 7]. Recall that the antigen concentration has been effectively normalized, so that  $A \leq 1$ . For patients 1, 4, 5, 7, 8, 9, and 11,  $K \gg 1$  (Table 3). Thus the denominator in the T cell activation term is approximately equal to  $K$ , and the activation/proliferation rate is  $\sim \frac{a}{K}$ . Substituting in  $K$  and  $a$  values [Table 2] for these patients yields rates ranging from  $0.02 \text{ d}^{-1}$  to  $0.06 \text{ d}^{-1}$  (mean  $0.0278 \text{ d}^{-1}$ ) with most values clustered around  $0.022 \text{ d}^{-1}$ . These patients all had low values for the T-cell activation/proliferation term, and later peaks (21 days) in observed and modeled viremia. Note that patient 5 had early observed viremia which we could not

model with this system, and the value of the ‘activation term’ for this patient reflects the later peak in the modeled viremia.

Higher values of the activation term would increase the interaction between T-cells and antigen A, resulting in swifter activation of T-cells and an earlier increase in virus. For patients 2, 3, 6, and 10 of which we modeled 3, 6, and 10 successfully,  $A$  and  $K$  were the same order of magnitude or within one order of magnitude in value, and the approximation for the interaction term shown above does not hold. In this case, interaction terms for these patients ranged from  $0.375 \text{ d}^{-1}$  to  $3.4 \text{ d}^{-1}$ , which is between one and two orders of magnitude greater than the interaction terms found for the prior group of ‘late peaking’ patients. Patients 3, 6, 10 and 13 all had early viremia, and relatively high values for the antigen clearance term  $\gamma$ .

## 5 Discussion and Summary

With a simple modification of a standard HIV-infection model we were able to reproduce the general features of the post-vaccination rise in viral load seen by Stanley et al. [1996]. Interestingly, more than half of the patients in this study had double peaks in viremia. While assay variability might account for some of these peaks, in other cases the peaks were sufficiently large that this seems unlikely. For patients with double peaks we were only able to fit the later of the two peaks, which was often the larger peak. When the peaks were of equal amplitude, we were again able to model the second of the two peaks. These patients were assigned lower pathogen clearance rates  $\gamma$  than patients with early single peaks in viremia, which we also successfully modeled.

The fact that we could not approximate the earlier peaks in those patients with double peaks in viremia suggests that our model may lack some features present in the actual biology. For example, individuals vaccinated recently may have a larger and more robust memory cell response than individuals vaccinated a long time in the past. The two peaks may represent an early memory response followed by a naive cell response. In individuals with little remaining memory, one may speculate that only the later naive response would be observed. Another possible explanation for double peaks is that the first peak is due to stimulation and infection of tetanus specific T cells, whereas the second peak is caused by the rise in viremia stimulating HIV specific T cells, and then allowing these cells to be infected. Thus, our model might benefit from the addition of other populations of T-cells.

Modeling of this type would also benefit from closer observation of patients: more data points, at closer time spacing, and better information on vaccination history, especially date of last tetanus booster.



## **Acknowledgements**

This work was performed under the auspices of the U.S. Department of Energy and was supported by NIH grants AI28433 and RR06555.

## References

- [1] Bentwich, Z., A. Kalkinovich, and Z. Weisman, Immune activation is a dominant factor in the pathogenesis of African AIDS, *Immunol. Today*, 16: 187–191, 1995.
- [2] Brichacek, B., S. Swindells, E. N. Janoff, S. Pirruccello, and M. Stevenson, Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine, *J. Infect. Dis.*, 174: 1191–1199, 1996.
- [3] Bukrinsky, M. I., T. L. Stanwick, M. P. Demsey, and M. Stevenson, Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection, *Science*, 254: 423–427, 1991.
- [4] Callaway, D. and A. S. Perelson, HIV-1 infection and low steady-state viral loads, submitted to *Bull. Mathematical Biology*, May 2001.
- [5] Chun, T.-W., L. Carruth, D. Finzi, X. Shen, J. A. DiGiuseppe, H. Taylor, M. Hermankova, K. Chadwick, J. Margolick, T. C. Quinn, Y.-H. Kuo, R. Brookmeyer, M. A. Zeiger, P. Barditch-Crovo and R. F. Siliciano, Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection, *Nature*, 387:183–187, 1997.
- [6] Fauci, A. S., Multifactorial nature of human immunodeficiency virus disease: implications for therapy, *Science* 262:1011–1018, 1993.
- [7] Folks, T., J. Kelly, S. Benn et al., Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV, *J. Immunol.*, 136: 4049–4053, 1986.
- [8] Ferguson N. M., F. deWolf, A. C. Ghani, C. Fraser, C. A. Donnelly, P. Reiss, J. M. Lange, S. A. Danner, G. P. Garnett, J. Goudsmit, and R. M. Anderson, Antigen-driven CD4+ T-cell and HIV-1 dynamics: residual viral replication under highly active antiretroviral therapy, *Proc Natl Acad Sci USA*, 96:15167–72, 1999.
- [9] Giorgi, J. V. and R. Detels, *Clin. Immunol. Immunopathol.*, 52:10–18, 1989.
- [10] Glesby, M. J., D. R. Hoover, H. Farzadegan, J. B. Margolick, and A. J. Saah, The effects of influenza vaccination on human immunodeficiency virus type 1 load: a randomized, double-blind, placebo-controlled study, *J. Infect. Dis.*, 174: 1332–1226, 1996.
- [11] Levacher, M., S. Tallet, M. Dazza, E. Dournon, B. Rouveix, and J. J. Pocidalo, *Clin. Exp. Immunol.*, 81: 177–182, 1990.
- [12] McLean, A. R., and M. A. Nowak, Models of interactions between HIV and other pathogens, *J. Theor. Biol.*, 155:69–102, 1992.
- [13] Medley, G. F., R. M. Anderson, D. R. Cox, and I. L. Billard, Incubation period of AIDS in patients infected via blood transfusion, *Nature*, 328:719–721, 1987.

- [14] Mittler, J. E., M. Markowitz, D. D. Ho and A. S. Perelson, Improved estimates for HIV-1 clearance rate and intracellular delay, *AIDS*, 13:1415–7, 1999.
- [15] Mohri, H., S. Bonhoeffer, S. Monard, A. S. Perelson and D. D. Ho, Rapid turnover of T-lymphocytes in SIV-infected rhesus macaques, *Science*, 279: 1223-7, 1998.
- [16] Nowack, M. A. and R. M. May, Virus dynamics: mathematical principles of immunology and virology, Chapter 3 (pp. 16–26), Oxford University Press, 2000.
- [17] O’Brien, W. A., K. Grovit-Ferbas, A. Namazi, J. Q. Zhao, A. Diagne, K. Idler, J. A. Zack, and I. S. Y. Chen, Human immunodeficiency virus type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination, *Blood*, 86:1082–1089, 1995.
- [18] Perelson, A. S., P. Essunger, Y. Cao, M. Vesanen, A. Hurley, K. Saksela, M. Markowitz and D. D. Ho, Decay characteristics of HIV-1 infected compartments during combination therapy, *Nature*, 387:188-191, 1997.
- [19] Perelson, A. S., A. U. Neumann, M. Markowitz, J. M. Leonard, and D. D. Ho, HIV-1 Dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time, *Science*, 271:1582-6, 1996.
- [20] Stanley, S. K., M. A. Ostrowski, J. S. Justement, K. Gantt, S. Hedayati, M. Mannix, K. Roche, D. J. Schwartzentruber, C. H. Fox, and A. S. Fauci, Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1, *N. Engl. J. Med.* 334:1222–1230, 1996.
- [21] Wahl, S. M. and J. M. Orenstein, Immune stimulation and HIV-1 replication, *J. Leukocyte Biol.*, 62:67–71, 1997.
- [22] Weissman, D., T. D. Barker and A. S. Fauci, The efficiency of acute infection of CD4+ T cells is markedly enhanced in the setting of antigen-specific immune activation, *J. Exp. Med.*, 183:687–692, 1996.
- [23] Zack, J. A., S. Arrigo, S. R. Weitsman, A. S. Go, A. Haislip and I. S. Y. Chen, HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure, *Cell*, 61:213-222:1990.
- [24] Zhang, Z-Q, T. Schuler, M. Zupancic, S. Wietgreffe, K. A. Staskus, K. A. Reimann, T. A. Reinhart, M. Rogan, W. Cavert, C. J. Miller, R. S. Veasey, D. Notermans, S. Little, S. A. Danner, D. D. Richman, D. Havlir, J. Wong, H. L. Jordan, T. W. Schacker, P. Racz, K. Tenner-Racz, N. L. Letvin, S. Wolinsky and A. T. Haase, Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells, *Science*, 286:1353–1357, 1999.




Figure 1: Plot of patient data showing viral loads for patients experiencing two distinct peaks in viremia at roughly 7 and 21 days. Patients 8 (in green line) and 9 (blue line) have equal or nearly equal peaks at days 7 and 21, while patients 1, 7, and 11 (black, red, and yellow line respectively) experience what was recorded as a minor peak at 7 days followed by a true peak at 21 days.




Figure 2: Plot of patient data showing viral loads for patients experiencing one early primary peak in viremia at 7 days. Patients 3, 5, 6, and 10 are shown in black, red, green and blue line respectively. Note that the curves for most of these patients show a post-peak 'shoulder' at 21-28 days.




Figure 3: Modeled viral loads for patient 3 (solid red line) are shown compared with observed viral loads (solid black line). Note that the sampling for the data is such that the data curve is slightly asymmetric, and true peak may not be sampled. Modeled viral loads slightly overshoot the observed, and modeled peak is somewhat later, but falls plausibly between two observations.




Figure 4: Modeled viral loads for patient 6 (solid red line) are shown plotted against observed viral loads (solid black line). This patient experienced a second very late peak (42 days) associated with known cavitory pneumonia, so data is truncated at 28 days. Note the asymmetry of the observed primary peak in viremia.




Figure 5: Modeled viral loads for patient 10 (solid red line) are shown plotted against observed viral loads (solid black line). Note that the modeled peak amplitude overshoots the data peak very slightly, though this misfit is probably within measurement error associated with the observations.




Figure 6: Modeled viral loads for patient 7, against data showing a minor peak in viremia followed by a maximum at 21 days. Observed is shown in black line; modeled viral loads in solid red line.




Figure 7: Modeled viral loads for patient 8 (solid red line) shown plotted against observed viral loads (solid black line) which show approximately equal-amplitude maxima at about 7 and 21 days.




Figure 8: Modeled viral loads for patient 9 (solid red line) shown plotted against observed viral loads (solid black line), again showing equal amplitude maxima at 7 and 21 days.